1	APOE Genotype-specific Methylation Patterns are Linked to Alzheimer
2	Disease Pathology and Estrogen Response
3	
4	Rebecca Panitch ¹ , Nathan Sahelijo ¹ , Junming Hu ¹ , the Alzheimer's Disease Neuroimaging
5	Initiative, Kwangsik Nho ^{10,11} , David A. Bennett ¹² , Kathryn L. Lunetta ⁶ , Rhoda Au ^{2,3,7} , Thor D.
6	Stein ^{5,8,9} , Lindsay A. Farrer ^{1,2,4,6,7,*} , Gyungah R. Jun ^{1,4,6,*}
7	
8	Departments of ¹ Medicine (Biomedical Genetics), ² Neurology, ³ Anatomy & Neurobiology,
9	⁴ Ophthalmology, ⁵ Pathology & Laboratory Medicine, and Boston University School of
10	Medicine, 72 East Concord Street, Boston, MA 02118, USA.
11	Departments of ⁶ Biostatistics and ⁷ Epidemiology, Boston University School of Public Health,
12	715 Albany Street, Boston, MA 02118, USA.
13	⁸ VA Bedford Healthcare System, Bedford, MA 01730, USA.
14	⁹ VA Boston Healthcare Center, Boston, MA 02130, USA ⁻
15	¹⁰ Department of Radiology and Imaging Sciences and Indiana Alzheimer's Disease Research
16	Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
17	¹¹ Center for Computational Biology and Bioinformatics, Indiana University School of Medicine,
18	¹² Rush Alzheimer's Disease Center, Rush University Medical Center, 1750 W. Harrison Street,
19	Suite 1000, Chicago, IL 60612, USA.
20 21	* Address Correspondence to:

Lindsay A. Farrer, PhD, Department of Medicine (Biomedical Genetics), Boston University
School of Medicine, 72 East Concord Street, Boston, MA 02118, USA 02118, email:

24 <u>farrer@bu.edu;</u>

Gyungah R. Jun, PhD, Department of Medicine (Biomedical Genetics), Boston University
School of Medicine, 72 East Concord Street, Boston, MA 02118, USA 02118, email:
gyungah@bu.edu.

28 Abstract:

29 The joint effects of APOE genotype and DNA methylation on Alzheimer disease (AD) risk is 30 relatively unknown. We conducted genome-wide methylation analyses using 2,021 samples in 31 blood (91 AD cases, 329 mild cognitive impairment, 1,391 controls) and 697 samples in brain 32 (417 AD cases, 280 controls). We identified differentially methylated levels in AD compared to 33 controls in an APOE genotype-specific manner at 25 cytosine-phosphate-guanine (CpG) sites in 34 brain and 36 CpG sites in blood. Additionally, we identified seven CpG sites in the APOE region containing TOMM40, APOE, and APOC1 genes with $P < 5x10^{-8}$ between APOE ε 4 carriers and 35 36 non-carriers in brain or blood. In brain, the most significant CpG site hypomethylated in ε 4 37 carriers compared to non-carriers) was from the TOMM40 in the total sample, while most of the 38 evidence was derived from AD cases. However, the CpG site was not significantly modulating 39 expression of these three genes in brain. Three CpG sites from the APOE were hypermethylated 40 in APOE E4 carriers in brain or blood compared in E4 non-carriers and nominally significant with 41 APOE expression in brain. Three CpG sites from the APOC1 were hypermethylated in blood, 42 which one of the 3 CpG sites significantly lowered APOC1 expression in blood using all subjects 43 or ɛ4 non-carriers. Co-methylation network analysis in blood and brain detected eight 44 methylation networks associated with AD and APOE $\varepsilon 4$ status. Five of the eight networks 45 included genes containing network CpGs that were significantly enriched for estradiol 46 perturbation, where four of the five networks were enriched for the estrogen response pathway. 47 Our findings provide further evidence of the role of APOE genotype on methylation levels 48 associated with AD, especially linked to estrogen response pathway.

49 Introduction

50	Alzheimer disease (AD) is a neurodegenerative disorder characterized neuropathologically by
51	neurofibrillary tangles and amyloid plaques [1]. The apolipoprotein E (APOE) E4 variant is the
52	strongest genetic risk factor for late-onset AD, while the $\epsilon 2$ variant has been shown to confer
53	protection against AD, in a dose-dependent manner [2,3,4]. Single copies of the ϵ 4 and ϵ 2 alleles
54	are associated with 3 to 4-fold increased and 0.61-fold decreased risk of AD, respectively.
55	Previous studies identified APOE genotype-specific mechanisms including the complement
56	pathway and blood-brain barrier dysfunction [5,6,7].
57	Large-scale genome-wide association studies (GWAS) have identified contributions to
58	AD risk from more than 75 independent loci, but the large portion of heritability of the disease is
59	unexplained [8]. Emerging omics technologies have prompted investigations of gene expression
60	and epigenetic profiles at the tissue and cellular levels. For example, it has been shown that the
61	degree of methylation of cytosine-phosphate-guanine (CpG) dinucleotides in brain differ
62	between AD cases and controls in novel regions as well as in loci previously associated with AD
63	risk such as BIN1 [9]. Methylation levels at multiple CpG sites assessed in peripheral blood have
64	also been associated with cognitive decline and AD progression [10].
65	Several CpG sites in the APOE region are differentially methylated in AD cases

66 compared to controls, and distinct methylation patterns have been observed between persons 67 with the $\varepsilon 3/\varepsilon 3$ and $\varepsilon 3/\varepsilon 4$ genotypes [11]. In addition, the *APOE* region has been shown to be 68 differentially methylated between healthy $\varepsilon 2$ and $\varepsilon 4$ carriers in blood [12]. However, despite 69 these findings, the effect of *APOE* genotypes, especially on the genome-wide level for AD risk 70 remains relatively unknown. Here, we analyzed methylation array data from blood and brain

- 71 tissue in three datasets to discover APOE genotype-dependent genome-wide associations of
- 72 methylation with AD risk and related traits, as well as co-methylation networks.

73

74 Methods

75 Sources of Methylation and Phenotypic Data

76 Data were obtained for participants of three cohort studies including the Religious Orders Study

and Rush Memory and Aging Project (ROSMAP), Alzheimer's Disease Neuroimaging Initiative

78 (ADNI), and Framingham Heart Study (FHS).

79 Religious Orders Study and Rush Memory and Aging Project (ROSMAP): Clinical,

- 80 neuropathological information, APOE genotyping, and preprocessed, quality controlled, and
- 81 normalized brain HumanMethylation450 BeadChip methylation array data derived from
- 82 dorsolateral prefrontal cortex area tissue donated by 697 ROSMAP participants (417 autopsy-
- 83 confirmed AD cases and 280 controls) [13,14,15] were obtained from the CommonMind
- 84 Consortium portal (http://www.synapse.org) (Supplementary Table 1). AD diagnosis was
- 85 determined using National Institute of Aging (NIA) Reagan criteria for intermediate or high
- 86 probability of AD [16]. AD-related traits included Braak staging for neurofibrillary tangles [17]
- 87 and the Consortium to Establish a Registry for Alzheimer Disease (CERAD) semi-quantitative
- criteria for measuring neuritic plaques (CERAD Score) [18]. ROS and MAP were both approved
- 89 by an Institutional Review Board of Rush University Medical Center. All participants signed an
- 90 informed consent, Anatomic Gift Act, and repository consent.

91 <u>Alzheimer's Disease Neuroimaging Initiative (ADNI)</u>: Infinium® MethylationEPIC BeadChip

- 92 beta values and phenotype data were obtained from the LONI website (http://adni.loni.usc.edu)
- for 630 ADNI participants including 91 with a clinical AD diagnosis, 329 with mild cognitive

94 impairment (MCI), and 210 controls [10]. Methylation array iDAT files were processed and 95 normalized using wateRmelon [19]. Because methylation was measured in DNA extracted from 96 blood specimens obtained at multiple examinations, methylation data from the earliest timepoint 97 were analyzed. Among the available endophenotypic data, analyses included magnetic resonance 98 imaging (MRI) volumetric measures of ventricles, and hippocampus, and entorhinal thickness, as 99 well as neuropsychological test scores consisted of the Alzheimer's Disease Assessment Scale – 100 13 item (ADAS13), Clinical Dementia Rating Scale Sum of Boxes (CDRSB), logical memory -101 delayed recall (LDELTOTAL), Rey Auditory Verbal Learning Test (RAVLT) immediate, 102 RAVLT learning, and RAVLT percent forgetting. 103 Framingham Heart Study (FHS): Cognitive test and normalized HumanMethylation450 104 BeadChip methylation array data were obtained for 1,391 cognitively healthy participants from 105 the generation 3 cohort in FHS [20]. Cognitive test scores at the same time point of methylation 106 measurement included the Paired Associate Learning - Recognition (PASr) test, Logical 107 Memories – Immediate Recall (LMi) test, Logical Memories – Delayed Recall (LMd) test, 108 Similarities Test (SIM), Visual Reproductions – Delayed Recall (VRd), Trail A (trailsA) test, the 109 animal portion of the Verbal Fluency Test (FAS_animal), and Boston Naming Test (BNT30). 110 **Differential Methylation Analysis** 111 Differential methylation between AD and control samples was performed in the ADNI and 112 ROSMAP datasets using the LIMMA software [21]. The methylation percentage of each CpG

site, defined as the proportion of total signal from the methylation-specific probe, was compared

- between AD cases and controls using linear regression models including sex, age, and batch as
- 115 covariates. Genome-wide methylation analyses were conducted in the total sample and
- 116 separately within APOE ε 4 carriers (ε 2/ ε 4, ε 3/ ε 4, and ε 4/ ε 4) and non-carriers (ε 2/ ε 2, ε 2/ ε 3, and

117	$\varepsilon 3/\varepsilon 3$).	Genome-wide meth	vlation analysis	between APOE ε	4 carriers and	non-carriers was
	/ -		.,			

- 118 performed in the ADNI and ROSMAP datasets using LIMMA and regression models including
- terms for age, sex and batch in the total sample and separately within AD and control groups.
- 120 Genome-wide methylation analysis between APOE E4 carriers and non-carriers for each CpG
- 121 site was conducted in FHS using lmekin package in R and a linear mixed effect model
- 122 incorporating a genetic relatedness matrix (GRM) as a random effect with sex and age at exam as
- 123 covariates. The GRM was generated using genetic dosage data and the software GCTA [22] to
- account for familial relationships among 8,481 FHS participants.

125 Association of Methylation with Expression of Genes in the APOE Region

- 126 RNA-sequencing (RNA-seq) data derived from ROSMAP brains were obtained and processed as
- 127 previously described [7]. Matched RNA-seq and methylation data were available for 510
- 128 ROSMAP participants (297 AD cases, 213 controls). Normalized gene-expression microarray
- 129 data were obtained from the LONI website (http://adni.loni.usc.edu) for 159 ADNI subjects (42
- 130 AD cases, 117 controls) who also had matching methylation array data. Significantly methylated
- 131 CpG sites between APOE ε 4-carriers and non-carriers (p=5.0x10⁻⁸) in APOE region genes
- 132 (NECTIN2, APOC1, APOE, and TOMM40) were selected for further analysis. The association of
- 133 gene expression level and methylation levels at the CpG sites in the APOE region was evaluated
- using linear regression models with covariates including age, sex, RNA integrity number (RIN),
- 135 RNA batch, and methylation batch. Post-mortem interval (PMI) was included as an additional
- 136 covariate in analyses of the ROSMAP dataset that had this information. Analyses were
- 137 performed in the total sample and separately within APOE ε 4 carriers and non-carriers.

138 Association of Methylation with Phenotypic Traits

139 Ouantitative or semi-quantitative traits were rank-transformed after adjusting for age and sex as 140 previously described [23]. In the ROSMAP dataset, the association of CpG site methylation with 141 rank-transformed Braak stage and CERAD score was assessed using regression models including 142 batch as a covariate. In the ADNI dataset, the association of CpG site methylation with cognitive 143 test scores and imaging phenotypes were assessed using regression models including covariates 144 of batch and education for cognitive traits and of batch and intracranial volume for imaging 145 phenotypes. In the FHS dataset, we tested the association of methylation with cognitive test 146 scores using a linear mixed effects model accounting for education and family structure with the 147 GRM as covariates. Association models were evaluated in the total sample and separately within 148 groups of APOE E4 carriers and non-carriers.

149 **Co-methylation Network Analysis**

150 Co-methylation networks were generated with differentially methylated CpG sites (P < 0.05) 151 between APOE E4 carriers and non-carriers in the ADNI and ROSMAP datasets using the 152 weighted correlation network analysis (WGCNA) program [24]. Analyses in the ADNI dataset 153 also included data from 329 subjects with MCI. We selected four and six soft-power parameters 154 in the ADNI and ROSMAP datasets, respectively, as previously described [5]. CpG percentages 155 were hierarchically clustered using a dissimilatory topological overlap matrix (TOM). Modules 156 with a minimum of 100 CpG sites were created using dynamic tree cutting, networks with 157 similar eigenvalues and a height of 0 were merged using WGCNA's mergeCloseModules 158 function. The signedKME function assigned fuzzy module membership. We identified networks 159 exhibiting significantly different methylation levels of eigenvalues between APOE E4 carriers 160 and non-carriers and between AD cases and controls, determined by a student's t-test, which 161 were selected for subsequent analysis. Biological pathways (MSigDB_Hallmark_2020) and drug

perturbations (Drug_Perturbations_from_GEO_2014) for each network were identified using the
EnrichR program applied to genes containing CpG sites in significant networks [25]. QIAGEN
Ingenuity Pathway Analysis (IPA) software was used to create a biological network containing
overlapping genes across modules from the EnrichR analysis.

166

167 **Results**

168 Differentially methylated CpG sites between AD cases and controls

169 Methylation levels in 697 brain samples from ROSMAP participants and 301 blood samples

170 from ADNI participants were compared between AD cases and controls in the total sample, and

171 within APOE £4 carrier and non-carrier subgroups (Figure 1a and Supplementary Table 1). In

172 the combined datasets, there were no genome-wide significant ($P < 5x10^{-8}$) differentially

173 methylated CpG sites between AD cases and controls in those with or without ɛ4. However,

analysis of the brain data revealed, moderately different (P<10⁻⁵) methylation levels at 3 CpG

175 sites among ε4 carriers and 22 CpG sites among ε4 non-carriers (Table 1 and Supplementary

176 **Figure 1a**). Of the 25 CpG sites that were differentially methylated in either *APOE* genotype

subgroup, approximately half (13 CpG sites) were moderately differentially methylated in the

total sample. Most of the CpG sites that were differentially methylated among ɛ4 non-carriers

179 (20/25 = 80%) were significantly associated (P<2.0x10⁻³) with Braak stage and/or CERAD score

180 (Figure 1b and Supplementary Table 2). Methylation levels of two intergenic CpG sites

181 (cg05731218 and cg12307200) were lower in AD cases compared to controls in the total sample

- and associated with both Braak stage and CERAD score at a genome-wide significance level
- 183 ($P < 5 \times 10^{-8}$). The most significant association of methylation CpG sites located within genes were

184	observed for cg10907744 in <i>GPR133</i> with Braak stage ($P=5.8 \times 10^{-6}$) and CERAD score
185	$(P=4.6x10^{-6})$ and for cg19987111 in CHSY1 with Braak stage $(P=8.5x10^{-8})$.
186	Moderately significant differential methylation between AD cases and controls from
187	blood were observed in 21 CpG sites among ɛ4 carriers and 15 CpG sites in ɛ4 non-carriers

188 (Supplementary Table 3 and Supplementary Figure 1b). In contrast to the findings in the

189 brain data, none of these CpG sites were improved in significance in the total sample

190 (Supplementary Table 3). Methylation of the 15 CpG sites, eleven among ɛ4 carriers and four

among $\varepsilon 4$ non-carriers, was significantly (multiple testing correction P<1.4x10⁻³) associated with

192 performance on global and domain-specific cognitive tests, and/or MRI brain imaging measures

193 (Figure 1c). Methylation of the CpG site cg09825488 in *EXO5* was increased in AD cases

194 compared to controls in $\varepsilon 4$ non-carriers (P=2.9x10⁻⁶, **Supplementary Table 3**) and significantly

associated with both global cognitive tests and several domain specific cognitive tests

196 (Supplementary Table 4). Methylation of three CpG sites (cg00198525, cg18714484, and

197 cg25190513) in ɛ4 carriers was significantly associated with the volume of cortical brain regions

198 (Supplementary Table 4). Methylation at the cg18714484 in *CHEK1* was decreased in AD

199 cases compared to controls in $\varepsilon 4$ carriers (P=2.2x10⁻⁶; **Supplementary Table 3**) and inversely

associated with global cognitive ($P=1.8 \times 10^{-5}$), memory performance (4.2×10^{-5}) and ventricle

201 volume ($P=8.1 \times 10^{-4}$).

202

203 Differentially methylated CpG sites between APOE £4 carriers and non-carriers

Eight CpG sites were significantly differentially methylated $(5x10^{-8})$ between APOE ε 4 carriers

and non-carriers in the ADNI, FHS, and ROSMAP datasets, and seven of the 8 sites are located

within the *APOE* region (chr19:45380000-45430000) (Table 2 and Figure 2a). In brain,

207	cg02613937 located in <i>TOMM40</i> was the most significant CpG site (hypomethylated in ϵ 4
208	carriers compared to non-carriers) in the total sample ($P=1.3 \times 10^{-13}$) and most of the evidence was
209	derived from AD cases ($P=7.0x10^{-13}$). Methylation at the cg02613937 was not significantly
210	associated with expression of genes in the APOE region (Figure 2b). In contrast, three CpG sites
211	from the APOE were hypermethylated in APOE ɛ4 carriers in brain (cg14123992, cg04406254)
212	and blood (cg06750524) compared in ɛ4 non-carriers (Table 2, Figure 2a). Methylation at both
213	APOE CpG sites in brain was nominally associated (P<0.05) with the APOE expression in ε 4
214	carriers only (Figure 2b). Three CpG sites from the APOC1 in blood were significantly
215	hypomethylated in ɛ4 carriers compared to non-carriers in either AD cases (cg07773593) or
216	controls (cg23270113 and cg05644480). Methylation of cg07773593 was nominally significant
217	(p<0.05) with lower APOC1 expression in the total sample and ɛ4 non-carriers (Supplementary
218	Figure 2).
218 219	Figure 2). Among the significant CpG sites in the <i>APOE</i> region between ε4 carriers and non-carriers
218219220	Figure 2). Among the significant CpG sites in the APOE region between ε4 carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor
218219220221	Figure 2). Among the significant CpG sites in the APOE region between \$4 carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor memory performance measured by the VRd (P=0.04) test in FHS APOE \$4 carriers (Figure 2c)
218219220221222	Figure 2). Among the significant CpG sites in the APOE region between \$4\$ carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor memory performance measured by the VRd (P=0.04) test in FHS APOE \$4\$ carriers (Figure 2c and Supplementary Table 5). Increased methylation of cg23270113 and cg05644480 from the
 218 219 220 221 222 223 	Figure 2). Among the significant CpG sites in the APOE region between \$4 carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor memory performance measured by the VRd (P=0.04) test in FHS APOE \$4 carriers (Figure 2c and Supplementary Table 5). Increased methylation of cg23270113 and cg05644480 from the gene APOC1 was significantly associated with worse performance on trailsA (P=6.9x10 ⁻³), PASr
 218 219 220 221 222 223 224 	Figure 2). Among the significant CpG sites in the APOE region between ε4 carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor memory performance measured by the VRd (P=0.04) test in FHS APOE ε4 carriers (Figure 2c and Supplementary Table 5). Increased methylation of cg23270113 and cg05644480 from the gene APOC1 was significantly associated with worse performance on trailsA (P=6.9x10 ⁻³), PASr (P=6.7x10 ⁻³), and BNT30 (P=0.01) tests in ε4 non-carriers. In APOE ε4 carriers, lower
 218 219 220 221 222 223 224 225 	Figure 2). Among the significant CpG sites in the <i>APOE</i> region between ɛ4 carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor memory performance measured by the VRd (P=0.04) test in FHS <i>APOE</i> ɛ4 carriers (Figure 2c and Supplementary Table 5). Increased methylation of cg23270113 and cg05644480 from the gene <i>APOC1</i> was significantly associated with worse performance on trailsA (P=6.9x10 ⁻³), PASr (P=6.7x10 ⁻³), and BNT30 (P=0.01) tests in ɛ4 non-carriers. In <i>APOE</i> ɛ4 carriers, lower methylation at cg23270113 was associated with poor memory performance measured by the
 218 219 220 221 222 223 224 225 226 	Figure 2). Among the significant CpG sites in the <i>APOE</i> region between ɛ4 carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor memory performance measured by the VRd (P=0.04) test in FHS <i>APOE</i> ɛ4 carriers (Figure 2c and Supplementary Table 5). Increased methylation of cg23270113 and cg05644480 from the gene <i>APOC1</i> was significantly associated with worse performance on trailsA (P=6.9x10 ⁻³), PASr (P=6.7x10 ⁻³), and BNT30 (P=0.01) tests in ɛ4 non-carriers. In <i>APOE</i> ɛ4 carriers, lower methylation at cg23270113 was associated with poor memory performance measured by the LMd (P=0.05) and LMi (P=0.05) tests, and lower methylation at cg05644480 was associated
 218 219 220 221 222 223 224 225 226 227 	Figure 2). Among the significant CpG sites in the <i>APOE</i> region between ɛ4 carriers and non-carriers in the FHS dataset (Table 2), increased methylation in the cg06750524 was associated with poor memory performance measured by the VRd (P=0.04) test in FHS <i>APOE</i> ɛ4 carriers (Figure 2c and Supplementary Table 5). Increased methylation of cg23270113 and cg05644480 from the gene <i>APOC1</i> was significantly associated with worse performance on trailsA (P=6.9x10 ⁻³), PASr (P=6.7x10 ⁻³), and BNT30 (P=0.01) tests in ɛ4 non-carriers. In <i>APOE</i> ɛ4 carriers, lower methylation at cg23270113 was associated with poor memory performance measured by the LMd (P=0.05) and LMi (P=0.05) tests, and lower methylation at cg05644480 was associated with poor performance on the SIM (P=0.05).

228

229 Co-Methylation Networks

230 The average methylation level for each of five networks from brain data and three networks from 231 blood data was significantly different between AD and control subjects as well as between $\varepsilon 4$ 232 carriers and non-carriers (Table 3, Supplementary Figure 3, and Supplementary Figure 4). 233 Five networks (mod2, mod3, mod4, mod5, and mod8) were significantly enriched for eleven 234 pathways (Figure 3a). These five networks contained gene-sets including 60 genes that overlap 235 the networks and whose expression levels are modified by estradiol (Figure 3b and 236 **Supplementary Table 6**). These 60 genes were biologically connected as a subnetwork (Figure 237 3c). Four of these networks (excluding mod5) were enriched for the estrogen response early 238 pathway (**Table 3 and Figure 3a**). *GPR133*, a member of mod2 and mod3 networks, was differentially methylated between AD cases and controls lacking $\varepsilon 4$ (P=6.4x10⁻⁶) and 239 significantly associated with Braak stage ($P=5.8\times10^{-6}$) and CERAD score ($P=4.6\times10^{-6}$) (Table 1 240 241 and Supplementary Table 2). Mod5, the only network not enriched for estrogen response early, 242 was uniquely enriched for the E2F target pathway and for seven unique drug perturbation sets 243 (Table 3, Figure 3a, and Figure 3b). Mod2 was enriched for estradiol as well as enriched for 244 the complement pathway, mitotic spindles, and TGF-beta signaling (Figure 3a and Figure 3b). 245 Mod8 was the only blood network showing significant enrichment for drug perturbations and 246 biological pathways that overlapped significant modules derived from brain (Figure 3a and 247 Figure 3b).

248

249 **Discussion**

We identified 25 CpG sites in brain and 36 CpG sites in blood that were differentially methylated in AD cases compared to controls in an *APOE* genotype-specific manner. Multiple CpG sites in the *APOE* region were differentially methylated between ε 4 carriers and non-carriers in brain or

253 blood. Methylation of several of these CpG sites in blood was significantly associated with 254 performance on cognitive tests in either $\varepsilon 4$ carriers or non-carriers. Lastly, we derived eight 255 unique co-methylation networks across blood and brain showing significant differential 256 methylation patterns between AD cases and controls and between $\varepsilon 4$ carriers and non-carriers. 257 Five of eight (62.5%) networks included genes enriched for an estradiol drug perturbation gene-258 set and four of these 5 networks were involved in estrogen response pathway. These findings 259 suggest that AD-related methylation patterns are dependent on APOE genotype and may be 260 targeted by estrogen modulating drugs.

261 CpG sites in *GPR133* and *CHSY1* were hypermethylated in brain from AD cases lacking 262 APOE ε 4 and associated with measures of plaque and tangle pathology. GPR133 is a member of 263 the adhesion G protein-coupled receptor family, several of which have been implicated in AD 264 and proposed as potential drug targets for neurological disease [26]. A deletion in CHSY1 causes 265 an increased inflammatory response and hippocampal neurodegeneration in mice [27]. We also 266 observed blood hypomethylation at CpG sites from the CHEK1 gene in AD cases carrying APOE 267 E4. CHEK1 induces astrogliosis in AD brains and inhibits PP2A which was linked in APOE 268 genotype-specific patterns to AD and AD-related traits by GWAS, gene expression analysis, and 269 experimental studies [6,28].

Association of AD with variants in the *APOE* region has been extensively evaluated [29].
While the link between *APOE* isoforms and AD risk is well established, independent

associations for AD with other genes near the APOE gene including TOMM40 and APOC1 are

273 less conclusive because they often do not replicate across ethnic populations and are confounded

by high linkage disequilibrium with *APOE* variants [30,31]. However, methylation studies have

275 consistently shown unique and strong differential methylation patterns by APOE genotype in AD

cases and controls [11,12]. We confirmed decreased methylation on *APOC1* in blood and
increased methylation on *APOE* in brain among £4 carriers compared to non-carriers, while
decreased methylation of £4 carriers on *TOMM40* in brain. These results suggest possible distinct
contributions of the genes in the *APOE* region between blood and brain tissues through
differential regulation on methylation sites to AD risk. Future studies are necessary to understand
the exact mechanisms involved with methylation and AD between blood and brain tissues in an *APOE* genotype-specific manner.

283 We identified pathways enriched for genes in APOE genotype and AD-specific co-284 methylation networks that were derived from differentially methylated CpG sites between $\varepsilon 4$ 285 carriers and non-carriers in brain or blood. One of the brain networks was enriched for genes in 286 complement pathway that was previously linked to AD in an APOE genotype-specific manner 287 [5,6]. Five of the eight APOE ε 4 associated networks showed significant enrichment with genes 288 perturbed by a drug, estradiol. Estradiol has been associated with increased cognitive function in 289 both animals and humans [32]. Loss of estrogen in post-menopausal women has been associated 290 with increased AD risk [33] and estrogen replacement therapy has shown to decrease AD risk in 291 post-menopausal women [34], particularly among those under age 64 [35]. Furthermore, the 292 effect of estrogen use on AD risk may be limited to ε4 non-carriers [36]. A recent study showed 293 estrogen decreased amyloid- β accumulation in the hippocampus and cortex in mice lacking ϵ 4 294 [37].

Our study has several limitations. First, methylation data from a microarray platform in ADNI participants was different from the one used by FHS and ROSMAP. Therefore, direct replication of each CpG site among these studies was limited. Second, none of the FHS participants with methylation data had AD due to their relatively young age. Alternatively, we

299 evaluated cognitive performance data which served as a robust AD endophenotype. Third, 300 pathway enrichment analysis was conducted using genes with network CpG sites under the 301 assumption of each CpG site directly modulating the corresponding gene. This assumption may 302 not hold when the CpG site regulates a long-distant gene. Fourth, phenotype data were not 303 comparable across datasets; in particular, neuropathological measures (i.e., Braak stage and 304 CERAD score) were available for ROSMAP, whereas ADNI and FHS featured cognitive test 305 data. Finally, the datasets included in this study were too small to account for sex differences 306 after stratification by APOE genotype or AD status. As a result, we were unable to evaluate sex 307 effect, especially genes involved in estrogen response pathways. 308 In conclusion, we identified differentially methylated CpG sites in many genes including

APOE that were also associated with AD and related traits. Many of these associations were
 APOE genotype- or tissue-specific. AD and *APOE* genotype-specific methylation networks were
 linked to estrogen response and an estrogen replacement therapy, estradiol. Future studies are
 required to evaluate the contributions of methylation and *APOE* genotypes to beneficial effects
 of estrogen as an AD risk-lowering therapy.

314

315 List of abbreviations:

AD: Alzheimer's Disease, ADAS13: Alzheimer's Disease Assessment Scale – 13 item, ADNI:
Alzheimer's Disease Neuroimaging Initiative, BNT30: Boston Naming Test, CDRSB: Clinical
Dementia Rating Scale Sum of Boxes, CERAD: Consortium to Establish a Registry for
Alzheimer Disease, CpG: cytosine-phosphate-guanine, FAS_animal: animal portion of the
Verbal Fluency Test, FHS: Framingham Heart Study, GRM: genetic relatedness matrix, GWAS:
genome-wide association study, LDELTOTAL: logical memory - delayed recall, LMd: Logical

322	Memories - Delayed Recall, LMi: Logical Memories - Immediate Recall, MCI: mild cognitive
323	impairment, MRI: magnetic resonance imaging, PASr: Paired Associate Learning - Recognition,
324	PMI: post mortem interval, RAVLT: Rey Auditory Verbal Learning Test, RIN: RNA integrity
325	number, ROSMAP: Religious Orders Study and Rush Memory and Aging Project, RNA-seq:
326	RNA sequencing, SIM: Similarities Test, trailsA: Trail A, VRd: Visual Reproductions – Delayed
327	Recall, WGCNA: weighted gene correlation network analysis
328	
329	Acknowledgements
330	Not applicable
331	
332	Funding
333	This study was supported by the National Institute on Aging (NIA) grants, RF1AG057519,
334	R01AG069453, U01AG068057, U19AG068753, P30AG072978, U01AG032984,
335	R56AG069130, R01AG048927, U01AG062602, U01AG058654, RF1AG057768, and
336	RF1AG054156. ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819,
337	R01AG17917, R01AG36042, U01AG46152, and U01AG61356. FHS is supported by National
338	Heart, Lung and Blood Institute (75N92019D00031 and HHSN2682015000011).
339	
340	Availability of data and materials
341	FHS data are available on the dbGaP (Study Accession ID: phs000056.v5.p3). ROSMAP
342	resources can be requested at from the CommonMind Consortium portal
343	(http://www.synapse.org). Data used in preparation of this article were obtained from the
344	Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). As
345	such, the investigators within the ADNI contributed to the design and implementation of ADNI

- 346 and/or provided data but did not participate in analysis or writing of this report. A complete
- 347 listing of ADNI investigators can be found at: <u>http://adni.loni.usc.edu/wp-</u>
- 348 <u>content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</u>.
- 349

350 Authors' contributions

- 351 R.P., L.A.F., and G.R.J. conceived overall study design. R.P., K.L., and G.R.J. perceived
- 352 statistical analysis. R.P., N.P., and J.H. performed data analyses. D.A.B., K.N., and R.A.
- 353 provided cognitive test and imaging data as well as interpretation of the data from the ROSMAP,
- 354 ADNI, and FHS, respectively. T.D.S. conducted and provided neuropathological data using
- 355 autopsied brains. R.P., K.N., D.A.B., T.D.S., L.A.F., and G.R.J. reviewed and edited the
- 356 manuscript. G.R.J. and L.A.F. supervised and obtained funding for the project.
- 357

358 Ethics approval and consent to participate

- 359 The study protocol, design, and performance of the current study were approved by the Boston
- 360 University Institutional Review Board.
- 361
- 362 **Consent for publication**
- 363 Not applicable
- 364
- 365 **Competing interests**
- 366 All authors declare no competing interests.

367

368 **References**

- 369 1. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease.
- 370 Molecular Neurodegeneration. 2019;14:32.
- 2. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age,
- sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer
- 373 disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
- 374 JAMA. 1997;278:1349–1356.
- 375 3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.
- 376 Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset
- 377 families. Science. 1993;261:921–923.
- 378 4. Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ,
- et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a
 5,000-person neuropathological study. Nat Commun. 2020;11:1–11.
- 381 5. Panitch R, Hu J, Chung J, Zhu C, Meng G, Xia W, et al. Integrative brain transcriptome
- analysis links complement component 4 and HSPA2 to the APOE ε 2 protective effect in
- 383 Alzheimer disease. Mol Psychiatry. 2021:1–11.
- 384 6. Jun GR, You Y, Zhu C, Meng G, Chung J, Panitch R, et al. Protein phosphatase 2A and
- 385 complement component 4 are linked to the protective effect of APOE $\Box 2$ for Alzheimer's
- disease. Alzheimers Dement. 2022. 9 February 2022. https://doi.org/10.1002/alz.12607.
- 387 7. Panitch R, Hu J, Xia W, Bennett DA, Stein TD, Farrer LA, et al. Blood and brain
- 388 transcriptome analysis reveals APOE genotype-mediated and immune-related pathways
- involved in Alzheimer disease. Alzheimers Res Ther. 2022;14:30.

390	8.	Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New
391		insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet.
392		2022;54:412–436.
393	9.	De Jager P, Srivastava G, Lunnon K, Burgess J, Schalkwyk L, Yu L, et al. Alzheimery's
394		disease pathology is associated with early alterations in brain DNA methylation at ANK1,
395		BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17:1156–1163.
396	10.	Li QS, Vasanthakumar A, Davis JW, Idler KB, Nho K, Waring JF, et al. Association of
397		peripheral blood DNA methylation level with Alzheimer's disease progression. Clinical
398		Epigenetics. 2021;13:191.
399	11.	Foraker J, Millard SP, Leong L, Thomson Z, Chen S, Keene CD, et al. The APOE Gene is
400		Differentially Methylated in Alzheimer's Disease. J Alzheimers Dis. 2015;48:745–755.
401	12.	Walker RM, Vaher K, Bermingham ML, Morris SW, Bretherick AD, Zeng Y, et al.
402		Identification of epigenome-wide DNA methylation differences between carriers of APOE
403		ε4 and APOE ε2 alleles. Genome Medicine. 2021;13:1.
404	13.	Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, et al. TOMM40'523
405		variant and cognitive decline in older persons with APOE $\varepsilon 3/3$ genotype. Neurology.
406		2017;88:661–668.
407	14.	De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, et al. A multi-omic atlas of
408		the human frontal cortex for aging and Alzheimer's disease research. Sci Data.
409		2018;5:180142.
410	15.	Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious
411		Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64:S161–S189.

- 412 16. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National
- 413 Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment
- 414 of Alzheimer's disease. Alzheimers Dement. 2012;8:1–13.
- 415 17. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta
- 416 Neuropathol. 1991;82:239–259.
- 417 18. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium
- 418 to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the
- 419 neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–486.
- 420 19. Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven
- 421 approach to preprocessing Illumina 450K methylation array data. BMC Genomics.
 422 2013;14:293.
- 423 20. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, et al. The Third
- 424 Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart
- 425 Study: Design, Recruitment, and Initial Examination. American Journal of Epidemiology.
- 426 2007;165:1328–1335.
- 427 21. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
 428 expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.
- 429 2015;43:e47–e47.
- 430 22. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait
 431 analysis. Am J Hum Genet. 2011;88:76–82.
- 432 23. Jun G, Guo H, Klein BEK, Klein R, Wang JJ, Mitchell P, et al. EPHA2 Is Associated with
- 433 Age-Related Cortical Cataract in Mice and Humans. PLoS Genet. 2009;5:e1000584.

- 434 24. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network
- 435 analysis. BMC Bioinformatics. 2008;9:559.
- 436 25. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and
- 437 collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics.
- 438 2013;14:128.
- 439 26. Folts CJ, Giera S, Li T, Piao X. Adhesion G protein-coupled receptors as drug target for
 440 neurological diseases. Trends Pharmacol Sci. 2019;40:278–293.
- 441 27. Macke EL, Henningsen E, Jessen E, Zumwalde NA, Landowski M, Western DE, et al. Loss
- 442 of Chondroitin Sulfate Modification Causes Inflammation and Neurodegeneration in skt
- 443 Mice. Genetics. 2020;214:121–134.
- 28. Zhou Y, Liu X, Ma S, Zhang N, Yang D, Wang L, et al. ChK1 activation induces reactive
 astrogliosis through CIP2A/PP2A/STAT3 pathway in Alzheimer's disease. FASEB J.
- 446 2022;36:e22209.
- 447 29. Jun G, Vardarajan BN, Buros J, Yu C-E, Hawk MV, Dombroski BA, et al. Comprehensive
- 448 Search for Alzheimer Disease Susceptibility Loci in the APOE Region. Arch Neurol.
- 449 2012;69:1270–1279.
- 450 30. Zhou Q, Zhao F, Lv Z, Zheng C, Zheng W, Sun L, et al. Association between APOC1
- 451 Polymorphism and Alzheimer's Disease: A Case-Control Study and Meta-Analysis. PLoS
 452 One. 2014;9:e87017.
- 453 31. Chiba-Falek O, Gottschalk WK, Lutz MW. The effects of the TOMM40 poly-T alleles on
 454 Alzheimer's disease phenotypes. Alzheimers Dement. 2018;14:692–698.
- 455 32. Luine VN. Estradiol and cognitive function: Past, present and future. Horm Behav.
- 456 2014;66:602–618.

- 457 33. Ratnakumar A, Zimmerman SE, Jordan BA, Mar JC. Estrogen activates Alzheimer's
- 458 disease genes. Alzheimers Dement (N Y). 2019;5:906–917.
- 459 34. Song Y, Li S, Li X, Chen X, Wei Z, Liu Q, et al. The Effect of Estrogen Replacement
- 460 Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A
- 461 Meta-Analysis. Frontiers in Neuroscience. 2020;14.
- 462 35. Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, et al. Long
- 463 Term Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to
- 464 Women Aged 50–55 Years. JAMA Intern Med.
- 465 2013;173:10.1001/jamainternmed.2013.7727.
- 466 36. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive
- 467 decline: evidence of gene-environment interaction. Neurology. 2000;54:1949–1954.
- 468 37. Kunzler J, Youmans KL, Yu C, LaDu MJ, Tai L. APOE modulates the effect of estrogen
- therapy on A β accumulation EFAD-Tg mice. Neurosci Lett. 2014;560:131–136.
- 470

471 **Figure Legends:**

472 Figure 1: Differential methylation between AD cases and controls grouped by APOE E4 473 **carrier status.** (a) Study Design. Methylation array data were obtained from blood (2 datasets) 474 and frozen brain tissue (1 dataset). Methylation of CpG sites was compared between AD cases 475 and controls as well as between APOE $\varepsilon 4$ carriers and non-carriers. Association of methylation at 476 CpG sites with neuropathological, cognitive and imaging traits was also evaluated. CpG sites 477 with nominally significant P values (P<0.05) between APOE ε 4 carriers and non-carriers were 478 incorporated in co-methylation network analyses performed separately for data derived from 479 blood and brain. Finally, biological pathways and drug perturbations were identified from

480 analyses of co-methylation networks. Figure created with biorender.com. (b) Heatmap showing 481 association of neuropathological traits with methylation at CpG sites that were differentially methylated (P<10⁻⁵) between AD cases and controls. CpG sites whose degree of methylation was 482 significantly ($P < 2.0 \times 10^{-3}$) associated with multiple testing correction with at least one trait are 483 484 indicated by an asterisk. (c) Heatmap showing association of cognitive and MRI imaging traits with methylation at CpG sites that were differentially methylated ($P < 10^{-5}$) between AD cases and 485 486 controls. Direction of differential methylation between AD and controls in APOE E4 carriers or 487 non-carriers in blood was shown. CpG sites whose degree of methylation was significantly associated with at least one trait after multiple testing correction ($P < 1.4 \times 10^{-3}$) are indicated by an 488 489 asterisk.

490

491 Figure 2. Differential methylation in the APOE region between APOE E4 carriers and non-492 carriers. (a) Regional plot of the APOE region. Differential methylation between $\varepsilon 4$ carriers and 493 non-carriers is shown for the total sample (green line), AD cases (blue line), and controls (pink 494 line) across three datasets. X-axis represents CpG sites that were significantly differentially 495 methylated between APOE E4 carriers and non-carriers at a genome-wide significance level 496 $(P < 5x10^{-8})$. Y-axis indicates the log10 P-value of hypermethylation (> 0) or hypomethylation (< 497 0). (b) Heatmap showing association of methylation in brain with expression of APOE and 498 adjacent genes. Significant (P < 0.05) associations are indicated by an asterisk. (c) Heatmap 499 showing association of methylation in blood with cognitive test scores in the FHS dataset. 500 Significant (P<0.05) associations are indicated by an asterisk.

502	Figure 3. Co-methylation networks. Co-methylation networks included genes with
503	significantly differentially methylated CpG sites (P<0.05) between APOE ɛ4 carriers and non-
504	carriers. Bar plots indicate significant AD and APOE genotype-related co-methylation networks
505	containing genes enriched for (a) biological pathways and (b) drug perturbation gene-sets (i.e.,
506	genes whose expression is modified by a drug). Networks with significant pathway or drug gene-
507	set enrichment (adjusted P<0.05) are shown. (c) Biological subnetwork including genes from
508	multiple co-methylation networks enriched for genes whose expression is perturbed by estradiol.

CrrC Norma	Chr	Chr	Cha	Chr	Cha	Chr	Chr	Chr	Desition	Como	Tota	l Sample	APOE	e4 carriers	APOE ε4 non-carriers	
CpG Name	Chr	Position	Gene	Т	Р	Т	Р	Т	Р							
cg19533050	2	163175044	IFIH1	-1.23	0.22	-4.92	1.9x10 ⁻⁶	0.35	0.73							
cg23808213	2	166948291	SCN1A	-4.81	1.9x10 ⁻⁶	-1.17	0.24	-4.71	3.2x10 ⁻⁶							
cg05731218	2	216769199	intergenic	-7.06	4.2×10^{-12}	-2.97	3.3×10^{-3}	-5.15	3.7×10^{-7}							
cg04436449	3	185214835	TMEM41A	-4.43	1.1x10 ⁻⁵	-0.56	0.57	-4.62	4.9x10 ⁻⁶							
cg12307200	3	188664632	intergenic	-7.04	4.7×10^{-12}	-4.48	1.3×10^{-5}	-4.87	1.5x10 ⁻⁶							
cg16234490	4	77138082	FAM47E	-4.48	8.6x10 ⁻⁶	0.17	0.87	-4.97	9.2×10^{-7}							
cg24899806	7	119914282	KCND2	-3.77	1.8×10^{-4}	0.22	0.83	-4.51	8.2x10 ⁻⁶							
cg23831517	8	34182528	intergenic	4.25	2.5x10 ⁻⁵	-0.63	0.53	4.63	4.5x10 ⁻⁶							
cg14096074	9	34255149	KIF24	-4.40	1.3x10 ⁻⁵	-0.99	0.32	-4.66	4.0x10 ⁻⁶							
cg03727169	10	31418969	intergenic	-4.67	3.6x10 ⁻⁶	-1.60	0.11	-4.94	1.1x10 ⁻⁶							
cg01982597	10	50733420	ERCC6	-4.10	4.7x10 ⁻⁵	0.54	0.59	-4.64	4.4x10 ⁻⁶							
cg20326704	10	70321770	TET1	-1.57	0.12	-4.61	7.6x10 ⁻⁶	0.27	0.79							
cg04126866	10	85932763	C10orf99	-5.24	2.2×10^{-7}	-1.84	0.07	-4.59	5.5x10 ⁻⁶							
cg14882481	11	107437051	ALKBH8	-4.54	6.7x10 ⁻⁶	0.19	0.85	-4.89	1.4x10 ⁻⁶							
cg10907744	12	131589455	GPR133	4.97	8.6x10 ⁻⁷	2.56	0.01	4.56	6.4x10 ⁻⁶							
cg18708502	13	21588555	LATS2	4.19	3.1x10 ⁻⁵	-0.18	0.86	4.50	8.4x10 ⁻⁶							
cg16746221	14	20666088	OR11G2	-3.86	1.2×10^{-4}	-1.15	0.25	-4.49	8.7x10 ⁻⁶							
cg24231804	15	67316861	intergenic	-5.53	4.5x10 ⁻⁸	-1.73	0.09	-4.68	3.7x10 ⁻⁶							
cg14829066	15	88559141	NTRK3	-4.66	3.8x10 ⁻⁶	-1.06	0.29	-5.15	3.7×10^{-7}							
cg19987111	15	101747167	CHSY1	4.10	4.6x10 ⁻⁵	-1.65	0.10	4.75	2.7×10^{-6}							
cg02432274	16	88378468	intergenic	2.00	0.05	4.68	5.5x10 ⁻⁶	0.02	0.98							
cg05952786	17	48559485	RSAD1	-5.11	4.2×10^{-7}	-1.67	0.10	-4.87	1.5x10 ⁻⁶							
cg15503752	17	74639731	ST6GALNAC1	4.40	1.2×10^{-5}	-0.52	0.60	4.62	4.9x10 ⁻⁶							
cg05421550	19	4446485	UBXN6	-4.88	1.3x10 ⁻⁶	-1.66	0.10	-5.11	4.6×10^{-7}							
cg19612770	19	4475216	HDGF2	-4.82	1.7x10 ⁻⁶	-1.49	0.14	-4.73	2.9x10 ⁻⁶							

Table 1. Differentially methylated CpG sites in brain for AD in total, APOE E4 carriers, and non-carriers

Only CpG sites moderately ($P < 10^{-5}$) differentially methylated in either *APOE* ϵ 4 carriers and/or non-carriers were included. T: T-value, P: P-value

CnC Nome	and Name Chy Desition Source Con		Como	Total Sample		AD		Co	Control	
CpG Name	CIIr	POSITION	Source	Gene	Т	Р	Т	Р	Т	Р
cg05002071	11	76510323	FHS (blood)	intergenic	5.67	1.5x10 ⁻⁸	NA	NA	5.67	1.5x10 ⁻⁸
cg02613937	19	45395297	ROSMAP (brain)	TOMM40	-7.55	$1.3 x 10^{-13}$	-7.41	7.0×10^{-13}	-3.26	1.3x10 ⁻³
cg14123992	19	45407868	ROSMAP (brain)	APOE	6.74	3.4x10 ⁻¹¹	6.51	2.2×10^{-10}	2.93	3.7x10 ⁻³
cg04406254	19	45407945	ROSMAP (brain)	APOE	6.05	2.4x10 ⁻⁹	5.90	7.4x10 ⁻⁹	2.45	0.02
cg06750524	19	45409955	FHS (blood)	APOE	6.45	1.1×10^{-10}	NA	NA	6.45	1.1×10^{-10}
cg23270113	19	45417587	FHS (blood)	APOC1	-6.40	$1.5 x 10^{-10}$	NA	NA	-6.40	$1.5 x 10^{-10}$
cg07773593	19	45417793	ADNI (blood)	APOC1	-6.04	4.6x10 ⁻⁹	-3.00	3.6x10 ⁻³	-4.36	2.1x10 ⁻⁵
cg05644480	19	45418020	FHS (blood)	APOC1	-5.85	5.0x10 ⁻⁹	NA	NA	-5.85	5.0x10 ⁻⁹

Table 2. Differentially methylated CpG sites in brain for *APOE* \Box 4 status in total, AD cases, and controls

T: T-value, P: P-value. Only CpG sites significantly ($P < 5x10^{-8}$) differentially methylated between *APOE* ϵ 4 carriers and non-carriers in the total sample were included.

Module Name	Dataset	Size	AD P- value*	<i>APOE</i> P-value*	significant (FDR < 0.05) hallmark pathways	Significant (FDR < 0.05) drug perturbations					
Mod1	ROSMAP	288	0.03	2.0x10 ⁻⁴	NA	NA					
Mod2	ROSMAP	6395	2.6x10 ⁻⁴	3.1x10 ⁻⁵	UV Response Dn, Complement, Epithelial Mesenchymal Transition, Mitotic Spindle, Apical Junction, TGF-beta Signaling, Estrogen Response Early, Coagulation	estradiol					
Mod3	ROSMAP	4891	2.9x10 ⁻³	6.1x10 ⁻⁴	Coagulation, Myogenesis, UV Response Dn, Estrogen Response Early, Epithelial Mesenchymal Transition, Notch Signaling	estradiol, mycophenolate mofetil					
Mod4	ROSMAP	3043	2.4x10 ⁻³	4.9x10 ⁻³	Myogenesis, Estrogen Response Early	estradiol, letrozole					
Mod5	ROSMAP	1277	0.02	1.1x10 ⁻⁹	E2F Targets	imatinib, methotrexate, bexarotene, fulvestrant, estradiol, etoposide, tamoxifen, hydroquinone, docetaxel, paclitaxel, valproic acid, ethanol, plicamycin					
Mod6	ADNI	391	0.04	5.3x10 ⁻⁴	NA	NA					
Mod7	ADNI	148	0.04	0.04	NA	NA					
Mod8	ADNI	4167	4.0x10 ⁻³	0.01	UV Response Dn, Estrogen Response Early, Myogenesis, Apical Junction	doxorubicin, tamoxifen, cisplatin, estradiol, prednisolone, valproic acid, ethanol, rosiglitazone, plicamycin, carboplatin, paclitaxel, hydrocortisone, dexamethasone					
*AD and	ADOED	olugo /	dorived fr	om studen	*AD and ADOED values derived from student's t test between conditions of module signavelyes which indicate sware as methylati						

Table 3. Summar	ry of co-methylated networks from	ROSMAP and ADNI associated	with AD and <i>APOE</i> \Box 4 status
-----------------	-----------------------------------	----------------------------	-----------------------------------------

*AD and APOE P-values derived from student's t-test between conditions of module eigenvalues which indicate average methylation over the network.



а



